| Literature DB >> 31037474 |
Andrea Szűcs1, Anna Réka Kiss2, Ferenc Imre Suhai3, Attila Tóth3, Zsófia Gregor3, Márton Horváth3, Csilla Czimbalmos3, Ibolya Csécs3, Zsófia Dohy3, Liliána Erzsébet Szabó3, Béla Merkely3, Hajnalka Vágó3.
Abstract
The acquisition of short-axis (SA) cine magnetic resonance (MR) images after the administration of contrast agent (CA) is a common, time-saving technique, but a decreased difference in the blood-myocardium contrast on these steady-state free precession (SSFP) cine scans could change the calculated parameters when using threshold-based papillary and trabecular muscle (PTM) quantification. We studied the effect of CA on the parameters calculated from pre- and post-CA SA cine images in noncompaction cardiomyopathy (NC-CMP) and healthy (H) participants using a threshold-based module. A total of 39 individuals (20 patients and 19 healthy) were included prospectively in this study. After the pre-CA SA images were acquired, i.v. gadobutrol (GA) or gadobenate dimeglumine (GD) (GA vs. GD: NC-CMP = 12 vs. 8; C = 12 vs. 7) was administered, and SA scans were repeated after two minutes. A threshold-based PTM software was used for postprocessing. Pre-CA and post-CA SA images were analyzed, and the parameters were compared in both the NC-CMP and H groups. The left ventricular volumes were significantly larger, while the left ventricular myocardial (LVmass) and trabecular mass (LVtrab) values were significantly smaller on the post-CA scans (NC-CMP: pre-CA vs. post-CA, EDV: 74.0 ± 13.6 vs. 81.1 ± 16.3 ml/m2, ESV: 25.3 ± 7.3 vs. 30.1 ± 11.2 ml/m2, LVmass-ED: 82.5 ± 17.5 vs. 75.7 ± 15.9 g/m2, LVtrab-ED: 25.0 ± 6.6 vs. 18.9 ± 4.7 g/m2; Healthy: preCA vs. post-CA, EDV: 69.7 ± 11.9 vs. 72.2 ± 10.7 ml/m2, ESV: 22.6 ± 5.7 vs. 23.9 ± 6.3 ml/m2, LVmass-ED: 71.3 ± 13.6 vs. 68.7 ± 13.9 g/m2, LVtrab-ED: 19.4 ± 2.6 vs. 16.2 ± 3.0 g/m2; p < 0.05). The decreased blood-myocardium contrast difference on post-CA SSFP SA cine images leads to altered cardiac parameters when using threshold-based software for evaluation.Entities:
Keywords: Cardiac magnetic resonance; Contrast agent; Left ventricular noncompaction; Threshold-based trabecular quantification
Mesh:
Substances:
Year: 2019 PMID: 31037474 PMCID: PMC6700040 DOI: 10.1007/s10554-019-01587-9
Source DB: PubMed Journal: Int J Cardiovasc Imaging ISSN: 1569-5794 Impact factor: 2.357
Fig. 1Short axis images collected before (a) and after (b) injection of contrast agent
Baseline characteristics of the noncompaction cardiomyopathy and healthy study groups
| NC-CMP n = 20 | Healthy n = 19 | p | |
|---|---|---|---|
| Gadobutrol (n) | 12 | 12 | |
| Gadobenate dimenglumine (n) | 8 | 7 | |
| Age (years) | 41.7 ± 16.3 | 37.9 ± 16.6 | 0.4736 |
| EF (%) | 66.1 ± 5.2 | 67.8 ± 5.5 | 0.9747 |
| EDV (ml/m2) | 74.0 ± 13.6 | 69.7 ± 11.9 | 0.3013 |
| ESV (ml/m2) | 25.3 ± 7.3 | 22.6 ± 5.7 | 0.1957 |
| LV mass-ED (g/m2) | 82.5 ± 17.5* | 71.3 ± 13.6* | 0.0316* |
| LV trab-ED (g/m2) | 25.0 ± 6.6* | 19.4 ± 2.6* | 0.0016* |
The parameters are converted to body surface area
EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, LV mass-ED left ventricular end-diastolic myocardial mass, LV trab-ED left ventricular end-diastolic papillary and trabecular mass, NC-CMP noncompaction cardiomyopathy
*p < 0.05
Fig. 2Study protocol. Pre-CA: pre-contrast agent, post-CA: post-contrast agent, SA: short axis
Fig. 3Image analysis with the threshold-based papillary and trabeculated muscle quantification software. The green area represents the myocardial mass including the endocardial trabeculation of the left ventricle
Calculated parameters of the noncompaction cardiomyopathy and healthy study groups calculated from pre-contrast and post-contrast scans
| NC-CMP | Healthy | |||||
|---|---|---|---|---|---|---|
| Pre-CA | Post-CA | p | Pre-CA | Post-CA | p | |
| ESV (ml/m2) | 25.3 ± 7.3 | 30.1 ± 11.2 | 0.0059* | 22.6 ± 5.7 | 23.9 ± 6.3 | 0.0411* |
| EDV (ml/m2) | 74.0 ± 13.6 | 81.1 ± 16.3 | 0.0002* | 69.7 ± 11.9 | 72.2 ± 10.7 | 0.0121* |
| EF (%) | 66.1 ± 5.2 | 64.7 ± 5.8 | 0.1608 | 67.8 ± 5.5 | 67.1 ± 6.4 | 0.7086 |
| LV mass-ED (g/m2) | 82.5 ± 17.5 | 75.7 ± 15.9 | < 0.0001* | 71.3 ± 13.6 | 68.7 ± 13.9 | 0.0010* |
| LV trab-ED (g/m2) | 25.0 ± 6.6 | 18.9 ± 4.7 | < 0.0001* | 19.4 ± 2.6 | 16.2 ± 3.0 | < 0.0001* |
The parameters are converted to body surface area
EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, LV mass-ED left ventricular end-diastolic myocardial mass, LV trab-ED left ventricular end-diastolic papillary and trabecular mass, NC-CMP noncompaction cardiomyopathy, post-CA post- contrast agent, pre-CA pre- contrast agent
*p < 0.05
Comparing the effect of gadobutrol (GA) and gadobenate dimenglumine (GD) on the calculated parameters
| Pre-GA | Post-GA | p | Pre-GD | Post-GD | p | |
|---|---|---|---|---|---|---|
| NC-CMP | ||||||
| ESV (ml/m2) | 24.1 ± 7.2 | 28.9 ± 12.6 | 0.0269* | 27.2 ± 7.6 | 31.8 ± 9.0 | 0.0013* |
| EDV (ml/m2) | 71.7 ± 12.7 | 79.5 ± 17.8 | 0.0076* | 77.4 ± 15.0 | 83.6 ± 14.6 | 0.0046* |
| EF (%) | 66.6 ± 5.8 | 66.3 ± 5.3 | 0.8025 | 65.3 ± 4.4 | 62.4 ± 6.0 | 0.0425* |
| LV mass-ED (g/m2) | 81.4 ± 19.6 | 75.6 ± 17.4 | 0.0031* | 84.3 ± 15.0 | 75.9 ± 14.5 | 0.0008* |
| LV trab-ED (g/m2) | 24.7 ± 7.8 | 18.8 ± 5.1 | 0.0014* | 25.4 ± 4.9 | 19.1 ± 4.4 | 0.0001* |
| Healthy | ||||||
| ESV (ml/m2) | 22.5 ± 5.0 | 23.9 ± 6.1 | 0.0771 | 22.7 ± 7.1 | 23.9 ± 7.1 | 0.3054 |
| EDV (ml/m2) | 69.2 ± 9.5 | 71.2 ± 7.2 | 0.1627 | 70.5 ± 16.2 | 73.9 ± 15.6 | 0.0075* |
| EF (%) | 67.5 ± 5.9 | 66.7 ± 6.9 | 0.7334 | 68.2 ± 5.1 | 67.9 ± 5.7 | 0.8034 |
| LV mass-ED (g/m2) | 71.3 ± 12.3 | 68.4 ± 12.8 | 0.0065* | 71.3 ± 16.6 | 69.1 ± 16.5 | 0.0993 |
| LV trab-ED (g/m2) | 19.7 ± 2.2 | 16.4 ± 3.0 | 0.0001* | 19.0 ± 3.4 | 15.9 ± 3.4 | 0.0015* |
The parameters are converted to body surface area
EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, LV mass-ED left ventricular end-diastolic myocardial mass, LVtrab-ED left ventricular end-diastolic papillary and trabecular mass, NC-CMP non-compaction cardiomyopathy, post-GA post-gadobutrol, post-GD post- gadobenate gimenglumine, pre-GA pre-gadobutrol, pre-GD pre-gadobenate dimenglumine
*p < 0.05
Comparison of the gadobutrol (GA) and gedobenate dimenglumine (GD) receiving populations’ pre-and post-contrast scans
| Pre-CA | Post-CA | |||||
|---|---|---|---|---|---|---|
| GA | GD | p | GA | GD | p | |
| NC-CMP | ||||||
| ESV (ml/m2) | 42.3 ± 10.2 | 46.7 ± 8.1 | 0.9453 | 44.1 ± 10.8 | 49.6 ± 9.1 | 0.8438 |
| EDV (ml/m2) | 73.4 ± 11.3 | 77.4 ± 15.0 | 0.5701 | 81.5 ± 18.9 | 83.6 ± 14.6 | 0.8299 |
| EF (%) | 65.4 ± 6.3 | 65.3 ± 4.4 | 0.9484 | 64.4 ± 5.1 | 62.4 ± 6.0 | 0.5706 |
| LV mass-ED (g/m2) | 82.8 ± 17.2 | 84.3 ± 15.0 | 0.8513 | 77.0 ± 14.0 | 75.9 ± 14.5 | 0.8899 |
| LV trab-ED (g/m2) | 24.0 ± 6.3 | 25.4 ± 4.9 | 0.8919 | 19.4 ± 4.6 | 19.1 ± 4.4 | 0.8919 |
| Healthy | ||||||
| ESV (ml/m2) | 24.6 ± 3.8 | 22.7 ± 7.1 | 0.5245 | 25.5 ± 4.5 | 23.9 ± 7.1 | 0.6847 |
| EDV (ml/m2) | 72.1 ± 9.1 | 70.5 ± 16.2 | 0.8346 | 72.8 ± 8.1 | 73.9 ± 15.6 | 0.8715 |
| EF (%) | 65.6 ± 5.1 | 68.2 ± 5.1 | 0.4415 | 65.0 ± 4.5 | 67.9 ± 5.7 | 0.4459 |
| LV mass-ED (g/m2) | 72.5 ± 12.1 | 71.3 ± 16.6 | 0.8756 | 72.8 ± 8.1 | 73.9 ± 15.6 | 0.8715 |
| LV trab-ED (g/m2) | 19.7 ± 2.2 | 19.0 ± 3.4 | 0.6321 | 16.0 ± 2.6 | 15.9 ± 3.4 | 0.9451 |
The parameters are converted to body surface area
EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, LV mass-ED left ventricular end-diastolic myocardial mass, LVtrab-ED left ventricular end-diastolic papillary and trabecular mass, NC-CMP non-compaction cardiomyopathy, post-GA post-gadobutrol, post-GD post- gadobenate gimenglumine, pre-GA pre-gadobutrol, pre-GD pre-gadobenate dimenglumine
*p < 0.05